InflaRx NV
IFRX0.895USD
+0.070+8.42%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
60.63M시가총액
손실P/E TTM
자세한 내용은 InflaRx NV 회사
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
InflaRx NV 정보
종목 코드 IFRX
회사 이름InflaRx NV
상장일Nov 08, 2017
CEORiedemann (Niels C)
직원 수74
유형Ordinary Share
회계 연도 종료Nov 08
주소Winzerlaer Str. 2
도시JENA
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Germany
우편 번호07745
전화493641508180
웹사이트https://www.inflarx.de/
종목 코드 IFRX
상장일Nov 08, 2017
CEORiedemann (Niels C)
InflaRx NV의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
수익 분석
통화: USD마지막 업데이트: Wed, Mar 5
통화: USD마지막 업데이트: Wed, Mar 5
FY2022
FY2021
FY2020
FY2019
기업이 아직 관련 데이터를 공개하지 않았습니다.
지역별USD
이름
수익
비율
Germany
0.00
0.00%
United States
0.00
0.00%
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
주주
주주 유형
주주
주주
비율
Suvretta Capital Management, LLC
9.57%
BofA Global Research (US)
3.65%
683 Capital Management LLC
3.32%
RA Capital Management, LP
2.91%
Guo (Renfeng M.D.)
2.60%
기타
77.94%
주주
주주
비율
Suvretta Capital Management, LLC
9.57%
BofA Global Research (US)
3.65%
683 Capital Management LLC
3.32%
RA Capital Management, LP
2.91%
Guo (Renfeng M.D.)
2.60%
기타
77.94%
주주 유형
주주
비율
Hedge Fund
17.39%
Individual Investor
6.38%
Research Firm
5.02%
Venture Capital
2.91%
Investment Advisor
1.36%
Investment Advisor/Hedge Fund
1.05%
Bank and Trust
0.02%
기타
65.87%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
78
18.80M
27.75%
-4.64M
2025Q3
77
16.63M
24.55%
-5.58M
2025Q2
85
22.06M
37.46%
-406.65K
2025Q1
87
22.59M
33.65%
+61.67K
2024Q4
86
18.09M
26.94%
-3.90M
2024Q3
81
17.30M
28.32%
-4.75M
2024Q2
83
17.63M
29.02%
-4.11M
2024Q1
87
18.26M
30.09%
-4.67M
2023Q4
91
21.52M
35.62%
-5.82M
2023Q3
89
23.41M
42.05%
-4.60M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Suvretta Capital Management, LLC
6.48M
9.57%
--
--
Sep 30, 2025
BofA Global Research (US)
2.48M
3.65%
+2.48M
--
Sep 30, 2025
683 Capital Management LLC
2.25M
3.32%
-225.00K
-9.09%
Sep 30, 2025
RA Capital Management, LP
1.97M
2.91%
--
--
Sep 30, 2025
Guo (Renfeng M.D.)
1.76M
2.6%
--
--
Dec 31, 2024
Eversept Partners, LP
1.73M
2.55%
+90.20K
+5.50%
Sep 30, 2025
Riedemann (Niels C. M.D.)
1.07M
1.58%
--
--
Dec 31, 2024
Mark (Christian Kubler)
960.01K
1.42%
--
--
Dec 31, 2024
Ikarian Capital LLC
722.07K
1.07%
+17.06K
+2.42%
Sep 30, 2025
Morgan Stanley & Co. LLC
626.60K
0.92%
-66.75K
-9.63%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
